Due to the downward trend in respiratory viruses in Maryland, masking is no longer required but remains strongly recommended in Johns Hopkins Medicine clinical locations in Maryland. Read more.
The Johns Hopkins Center for Psychedelic and Consciousness Research is leading the way in exploring innovative treatments using psilocybin. The molecular structure of psilocybin, a naturally occurring psychedelic compound found in ‘magic mushrooms,’ allows it to penetrate the central nervous system and the scientific and medical experts are just beginning to understand its effects on the brain and mind and its potential as therapeutics for mental illnesses.
Backed by $55 million in funding, researchers build on previous work and expand research on psychedelics for illness and wellness: (1) to develop new treatments for a wider variety of psychiatric and behavioral disorders with the aspiration of treatments tailored to the specific needs of individual patients and (2) to expand research in healthy volunteers with the ultimate aspiration of opening new ways to support human thriving.
Roland Griffiths, an internationally revered researcher of psychedelic and mood-altering drugs, whose research helped kickstart a new era of psychedelic study and led to the creation of the nation’s first psychedelic research center, at Johns Hopkins, died on Monday, Oct. 16, at age 77.
Roland Griffiths, Ph.D., presented a TEDMED talk in 2015 about the therapeutic and consciousness potential of psilocybin. Research to date demonstrate safety of psilocybin in regulated spaces facilitated by medical team over a series of guided sessions; and as a part of cognitive behavioral therapy, psilocybin helps in reducing anxiety in some cancer patients, and in facilitating smoking cessation for some.
With controlled psychedelic substances, there is a potential to alter the entire brain for a period of time and thus provide relief from negative emotions that cloud the mind. Capturing this controlled relief, Dr Frederick Barrett's research suggests that, under the right conditions, psychedelics may have the potential to treat a wide range of mood and substance disorders.
A group of Johns Hopkins researchers was the first to obtain regulatory approval in the United States to resume research with psychedelics in healthy volunteers who had no previous experience with psychedelics.
The publication “Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance” on the safety and enduring positive effects of a single dose of psilocybin is widely considered the landmark study that sparked a renewal of psychedelic research world-wide.
See More Academic Papers
The Center’s team emphasizes safety as a cornerstone of psychedelics research. These recommended techniques in this publication, “Human hallucinogen research: guidelines for safety,” have been adopted by others in the field.
Read the Paper
Johns Hopkins researchers report that a small number of longtime smokers who had failed many attempts to drop the habit did so after a carefully controlled and monitored use of psilocybin, the active hallucinogenic agent in so-called “magic mushrooms,” in the context of a cognitive behavioral therapy treatment program.
Read the News Release
In a small double-blind study, Johns Hopkins researchers report that a substantial majority of people suffering cancer-related anxiety or depression found considerable relief for up to six months from a single large dose of psilocybin — the active compound in hallucinogenic “magic mushrooms.”
Read the News Release
In an evaluation of the safety and abuse research on the drug in hallucinogenic mushrooms, Johns Hopkins researchers suggest that if it clears phase III clinical trials, psilocybin should be re-categorized from a schedule I drug—one with no known medical potential—to a schedule IV drug such as prescription sleep aids, but with tighter control.
Read the News Release
Online survey of over 300 people with Alcohol Use Disorder reported reducing or abstaining alcohol use after taking a psychedelic drug such as psilocybin, LSD or DMT. This study adds to growing evidence for supporting further investigation of psychedelic-assisted treatment for alcoholism or substance abuse.
Read the Paper
A group of private donors has given $17 million to start the Center for Psychedelic and Consciousness Research at Johns Hopkins Medicine, making it what’s believed to be the first such research center in the U.S., and the largest research center of its kind in the world. In the absence of federal funding for such therapeutic research in people, the new center will rely on the gifts announced today to advance the emerging field of psychedelics for therapies and wellness.
Read the News Release
The brain scans after psilocybin use showed that the claustrum was less active, meaning the area of the brain believed responsible for setting attention and switching tasks is turned down when on the drug. The researchers say that this ties in with what people report as typical effects of psychedelic drugs, including feelings of being connected to everything and reduced senses of self or ego.
Read the News Release
In a small study of adults with major depression, Johns Hopkins Medicine researchers report that two doses of the psychedelic substance psilocybin, given with supportive psychotherapy, produced rapid and large reductions in depressive symptoms, with most participants showing improvement and half of study participants achieving remission through the four-week follow-up.
Read News Release
Johns Hopkins Medicine was awarded a grant from the National Institutes of Health (NIH) to explore the potential impacts of psilocybin on tobacco addiction. This is the first NIH grant awarded in over a half century to directly investigate the therapeutic effects of a classic psychedelic, consistent with a recent study published online that searched NIH funding and found zero grants were awarded between 2006 and 2020. Johns Hopkins Medicine will lead the multisite, three-year study in collaboration with University of Alabama at Birmingham and New York University.
Read the News Release
Previous studies by Johns Hopkins Medicine researchers showed that psychedelic treatment with psilocybin relieved major depressive disorder symptoms in adults for up to a month. Now, in a follow-up study of those participants, the researchers report that the substantial antidepressant effects of psilocybin-assisted therapy, given with supportive psychotherapy, may last at least a year for some patients.
Read the news release
At the Center, researchers focus on how psychedelics affect behavior, mood, cognition, brain function, and biological markers of health. Upcoming studies will determine the effectiveness of psilocybin as a new therapy for opioid addiction, Alzheimer’s disease, post-traumatic stress disorder (PTSD), post-treatment Lyme disease syndrome (formerly known as chronic Lyme disease), anorexia nervosa and alcohol use in people with major depression.